Mexidol Succinate

CAS No.: 127464-43-1
Other Names: Mexidol powder; Mexidol, Mexifin, 2-ethyl-6-methyl 3-hydroxypiridine
Molecular Formula: C8H11NO.C4H6O4
Molecular Weight: 255.27
Appearance: White to off white crystalline powder
Boiling point: 280.6 degree centigrade at 760 mmHg
Flashing point: 123.5 degree centigrade
Purity: 99%
Main Function: anxiolytic, nootropic, neuroprotective, antidepressant, anti-hypoxic, and anti-addictive

Application:
1. Use in neurology, therapeutics, psychiatry, surgery and addictology.
2. Emoxypine succinate offers anti-depressive, dermaprotective, and stress reducing.
3. Improves the cognitive function and brain health of patients with mental damage and disorders by increasing mitochondrial oxygen consumption.
4. Increases the average blood flow in patients with heart trouble, while also reducing oxidative stress.
5. Helps improve vision by way of increasing blood flow to the retinal artery.

Product Description:
Mexidol Succinate chemical structure resembles that of pyridoxine (a type of vitamin B6).It is an axiolytic nootropic with anticonvulsant, neuroprotective and anti-inflammatory actions. It improves cerebral bloodflow, lowers cholesterol and is cardioprotective. It also increases dopamine levels in the brain.
Mexidol Succinate is characterized by a wide spectrum of pharmacological effects, it has cerebroprotective, nootropic, antihypoxic, anxiolytic, antistress and anticonvulsant effects, eliminates the deficiency of CNS functions during aging.
Mexidol Succinate is a high-end antioxidant and antihypoxic drug with an unique multipurpose action mechanism. As a basis of antioxidant neuroprotection, Mexidol positively influences the main components of pathogenesis of a disease, connected with the processes of free-radicals oxidation and oxygen-dependent pathological conditions. Mexidol found a successful use in neurology, therapeutics, psychiatry, surgery and addictology.
Mexidol Succinate improves energy metabolism in the cell, which along with antioxidant action creates the basis for an antihypoxic effect. The drug has a modulating effect on the activity of membrane-bound enzymes and receptor complexes of brain cell membranes, in particular GABA-benzodiazepine and acetylcholine. He himself does not bind to these receptor structures, but changes the content of mediator monoamines and amino acids in the structures of the brain. Meksidol increases the level of dopamine and endogenous peptides, blocks the activity of serine proteinases and metalloproteases.